MedTrace Logo

10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies

NCT00997945 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2011-05-19

No results posted yet for this study

Summary

The purpose of this study is to assess the pharmacokinetics of single and multiple doses of 10mg ZD4054 (Zibotentan) in male, elderly Chinese patients with advanced solid malignancies.

Conditions

  • Advanced Solid Malignancies

Interventions

DRUG

ZD4054 (Zibotentan)

10 mg ZD4054 (Zibotentan) once daily on Day1, Day4 to Day15

Sponsors & Collaborators

Principal Investigators

  • Li Jin · The Cancer Hospital Affiliated Fudan University

  • Helen Lin · AstraZeneca China MC

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-09-30
Completion
2011-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00997945 on ClinicalTrials.gov